RecruitingPhase 3ACTRN12605000271606

Obstructive Sleep Apnoea and Cardiovascular Disease

The effects of short term hypoxia on arterial stiffness in subjects with obstructive sleep apnoea.

Sponsor

NHMRC

Enrollment

20 participants

Start Date

Apr 16, 2003

Study Type

Interventional

Conditions

Obstructive Sleep Apnoea (OSA)

Eligibility

Sex: Males

Plain Language Summary

Simplified for easier understanding

This study is looking at the connection between severe obstructive sleep apnoea (OSA) and heart disease in men. Sleep apnoea causes your breathing to repeatedly stop during the night, which puts stress on the heart and blood vessels. Researchers want to understand whether sleep apnoea itself causes changes that can lead to heart disease, and whether treating it with CPAP therapy improves heart health. You may be eligible if: - You are a male - You have severe obstructive sleep apnoea confirmed by a sleep study (Respiratory Disturbance Index of 25 or more) You may NOT be eligible if: - You have high blood pressure, high cholesterol, heart disease, or diabetes - You are a smoker - You are taking any medication for heart or breathing conditions Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Subjects will be exposed to short term hypoxia aiming for a target saturation of 80% while haemodynamic and ventilatory parameters are measured. They will breathe through a mouthpiece connected to

Subjects will be exposed to short term hypoxia aiming for a target saturation of 80% while haemodynamic and ventilatory parameters are measured. They will breathe through a mouthpiece connected to special equipment which delivers different gas mixtures and enables the delivery of the hypoxic exposure. Heart rate, blood pressure, arterial stiffness ( via pulse wave analysis), and peripheral vasoconstriction (via peripheral arterial tonometry PAT) will be measured. Initially there will be a 10 minute baseline period followed by the 20 minute period of hypoxia and then a 10 minute recovery period. A proportion of subjects will then be studied after being commenced on treatment with continuous positive airway pressure (CPAP).

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000271606

Related Trials

Feasibility of Upper Airway Stimulation in OSA

NCT073966491 location

A Study Assessing Adult Patients Referred to an NHS Sleep Service With Suspected Obstructive Sleep Apnoea. This Study Aims to Compare the Sunrise Wearable Diagnostic Device Performance and Potential Inclusion in a NHS Diagnostic Pathway With Oximetry and WatchPAT Which Are Currently Used.

NCT072694831 location